The Algerian pharmaceutical group Saidal has defended the legality of its pharmacies following a decision by the Caisse nationale de la sécurité sociale (CNAS) to suspend the tiers payant system. This system allows for the direct reimbursement of medication costs to patients. Saidal argues that its pharmacies operate on solid legal, administrative, and institutional grounds, established by an authorization to practice issued by the Ministry of Health on December 27, 1997.

The CNAS decision, effective November 15, affects both insured individuals and low-income uninsured persons, who can no longer have their medication costs covered under the tiers payant system at Saidal pharmacies. In response, Saidal cited the legal and administrative foundations of its pharmacies, emphasizing that the 1997 authorization remains in effect. The group also referenced a 2025 decision by the Conseil des participations de l’Etat, which entrusted it with managing the former national medication distribution enterprise, Endimed.

Saidal's defense of its pharmacies' legality centers on the argument that the 2018 health law did not explicitly or implicitly annul or invalidate the 1997 authorization. The group claims that there is no legal requirement for the authorization to be renewed. According to Saidal, the initial authorization and the transfer of management rights from Endimed form the basis of its pharmacies' legality. This stance, however, contrasts with the CNAS's concerns regarding the conformity of Saidal's status with current pharmacy regulations.

The CNAS suspension is based on information from the Ministry of Health and the Ministry of Labor, indicating that Saidal's pharmacies do not comply with the legal and regulatory framework governing pharmaceutical activities. Specifically, the 2018 health law stipulates that a pharmacist must be the sole owner and manager of a pharmacy. The CNAS argues that Saidal's public status, derived from its origins as Endimed, does not align with this requirement.

In reaction to the suspension, Saidal has opted for dialogue with concerned institutions to clarify the legal and regulatory aspects of its activities. The group aims to find solutions that will allow the resumption of the tiers payant system, ensuring that insured individuals' rights are preserved and their access to medication and pharmaceutical services is not adversely affected.

The suspension of the tiers payant system at Saidal pharmacies has practical implications for patients who regularly purchase medication from these outlets. Affected individuals are advised to obtain their CHIFA cards from Saidal pharmacies and then approach a private pharmacy contracted with CNAS to continue benefiting from the tiers payant system. This measure is intended to minimize disruptions to patients' treatments.

Saidal has reaffirmed its commitment to operating within the legal and regulatory framework of Algeria. The group is engaged in discussions with relevant parties to resolve the differences concerning its pharmacies' legal status and to restore the tiers payant system. The outcome of these interactions will be crucial in determining whether the suspension will be lifted and the tiers payant system reinstated for Saidal pharmacies.

Key points

  • Saidal cites a 1997 authorization from the Ministry of Health and a 2025 decision from the Conseil des participations de l’Etat as the basis for the legality of its pharmacies.
  • The CNAS suspension of the tiers payant system at Saidal pharmacies stems from concerns about non-compliance with current regulations requiring pharmacists to be the sole owners and managers of pharmacies.
  • Saidal is engaged in dialogue with concerned institutions to clarify the legal and regulatory aspects of its activities and aims to restore the tiers payant system.

Reporting sources

Share this story

Written by

SaharaWire Newsroom
SaharaWire

Reporting for SaharaWire from the Nairobi bureau.